New paradigms in fibroblast-immune cells coordination in matrix homeostasis in health and disease

健康和疾病基质稳态中成纤维细胞-免疫细胞协调的新范例

基本信息

  • 批准号:
    MR/W016796/1
  • 负责人:
  • 金额:
    $ 160.66万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Fellowship
  • 财政年份:
    2022
  • 资助国家:
    英国
  • 起止时间:
    2022 至 无数据
  • 项目状态:
    未结题

项目摘要

Collagen is the most abundant protein in the human body (~25% by mass), and is formed into long fibrils that provide structure to organs with very different functions and mechanical properties (e.g. giant parallel bundles in tendons, smooth flat lattices in lungs). This suggests a fine control of the cells in producing and assembling these long fibrils, and dysregulation of this control underpins many pathologies, including fibrosis, heart disease, and many age-related conditions such as proneness to fractures, skin looseness, and osteoarthritis. Convention dictates that different cells have different functions - notably fibroblasts are the key arbiters to collagen matrix formation, and immune cells are the removers; however, recently it has been discovered that immune cells directly contribute to the production of collagen. This highlights how despite collagen's clear fundamental importance, we still do not fully understand the process of its assembly and maintenance, in particular how different types of cells communicate and cooperate with one another in this process. This forms the basis and goals of my research. My recent work has shown that the circadian rhythm controls collagen production and secretion, and I have also discovered that a specialised compartment of the cells (known as the endosome) holds the key to the fate of collagen within the cells, i.e. whether they will be made into fibrils, simply secreted out of the cells, or degraded. Using new mass spectrometry approaches that I have pioneered, I aim to determine how this control of fibril formation happens at the molecular level, as knowledge of how to direct collagen between the different fates will allow for new therapeutic strategies for fibrosis - a disease characterised by an abundance of collagen fibrils that currently has no effective cure. Using the same mass spectrometry technique, I will further determine the molecular networks in immune cells that control collagen uptake, which may provide further insights to targeting fibrosis from a different angle. This knowledge will also be fundamental to other conditions heavily involving the immune system and matrix, including wound healing and cancer metastasis. I have also found that immune cells induce fibroblast circadian rhythms, and that fibroblasts and immune cells make more collagen fibrils when they are mixed together. I will interrogate this relationship and determine the proportion of collagen produced by each cell type in the mixtures, using state-of-the-art genetic modification and high throughput biochemical assays, providing important insights into how fibroblasts and immune cells communicate and coordinate in collagen deposition. As such, my work has important and fundamental implications to further our mechanistic understanding of fibrotic responses, in its broadest sense.
胶原蛋白是人体中含量最多的蛋白质(约占总量的25%),并形成长原纤维,为具有不同功能和机械特性的器官提供结构(例如肌腱中的巨大平行束,肺中的光滑扁平晶格)。这表明细胞在产生和组装这些长原纤维时受到良好的控制,而这种控制的失调是许多病理的基础,包括纤维化、心脏病和许多与年龄相关的疾病,如骨折、皮肤松弛和骨关节炎。传统观点认为,不同的细胞有不同的功能——尤其是成纤维细胞是胶原基质形成的关键仲裁者,而免疫细胞是清除者;然而,最近发现免疫细胞直接促进胶原蛋白的产生。这表明,尽管胶原蛋白具有明确的基础重要性,但我们仍然不完全了解其组装和维护的过程,特别是不同类型的细胞在此过程中如何相互沟通和合作。这构成了我研究的基础和目标。我最近的工作表明,昼夜节律控制着胶原蛋白的产生和分泌,我还发现细胞的一个特殊隔间(称为内核体)掌握着细胞内胶原蛋白命运的关键,即它们是否会被制成原纤维,简单地分泌出细胞,还是被降解。使用我开创的新的质谱分析方法,我的目标是确定纤维形成的控制是如何在分子水平上发生的,因为如何在不同命运之间指导胶原蛋白的知识将允许新的治疗纤维化的策略-一种以丰富的胶原原纤维为特征的疾病,目前尚无有效的治疗方法。使用相同的质谱技术,我将进一步确定免疫细胞中控制胶原摄取的分子网络,这可能从不同的角度为靶向纤维化提供进一步的见解。这一知识也将对其他严重涉及免疫系统和基质的疾病,包括伤口愈合和癌症转移,具有重要意义。我还发现,免疫细胞诱导成纤维细胞的昼夜节律,当成纤维细胞和免疫细胞混合在一起时,它们会产生更多的胶原原纤维。我将询问这种关系,并确定每种细胞类型在混合物中产生胶原蛋白的比例,使用最先进的基因修饰和高通量生化分析,为成纤维细胞和免疫细胞如何在胶原沉积中沟通和协调提供重要见解。因此,我的工作具有重要的和基本的意义,进一步我们的机制理解纤维化反应,在其最广泛的意义上。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Modeling collagen fibril self-assembly from extracellular medium in embryonic tendon.
胚胎肌腱细胞外介质中胶原纤维自组装的建模。
  • DOI:
    10.1016/j.bpj.2023.07.001
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    3.4
  • 作者:
    Revell CK
  • 通讯作者:
    Revell CK
The matrix in focus: new directions in extracellular matrix research from the 2021 ASMB hybrid meeting.
  • DOI:
    10.1242/bio.059156
  • 发表时间:
    2022-01-15
  • 期刊:
  • 影响因子:
    2.4
  • 作者:
    Nerger BA;Jones TM;Rose KWJ;Barqué A;Weinbaum JS;Petrie RJ;Chang J;Vanhoutte D;LaDuca K;Hubmacher D;Naba A
  • 通讯作者:
    Naba A
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joan Chang其他文献

The Function and Diagnostic Potential of Adipocyte-Derived Factors in the Tumor Microenvironment
脂肪细胞衍生因子在肿瘤微环境中的功能和诊断潜力
  • DOI:
    10.1007/978-3-319-39147-2_6
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    4.3
  • 作者:
    Joan Chang;A. Dudley
  • 通讯作者:
    A. Dudley
Circulating collagen type I fragments as specific biomarkers of cardiovascular outcome risk: Where are the opportunities?
循环中的I型胶原蛋白片段作为心血管预后风险的特异性生物标志物:机遇何在?
  • DOI:
    10.1016/j.matbio.2025.03.001
  • 发表时间:
    2025-05-01
  • 期刊:
  • 影响因子:
    4.800
  • 作者:
    Emily M. Martin;Joan Chang;Arantxa González;Federica Genovese
  • 通讯作者:
    Federica Genovese
Adenovirus‐mediated gene transfer of wild‐type p53 results in melanoma cell apoptosis in vitro and in vivo
腺病毒介导的野生型p53基因转移导致体外和体内黑色素瘤细胞凋亡
  • DOI:
  • 发表时间:
    1995
  • 期刊:
  • 影响因子:
    6.4
  • 作者:
    C. Cirielli;T. Riccioni;Chun‐Hung Yang;R. Pili;T. Gloe;Joan Chang;K. Inyaku;A. Passaniti;M. Capogrossi
  • 通讯作者:
    M. Capogrossi
Combat and Operational Stress Control Interventions and PTSD: A Systematic Review and Meta-Analysis.
战斗和作战压力控制干预措施和创伤后应激障碍:系统回顾和荟萃分析。
  • DOI:
    10.1093/milmed/usab310
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    1.2
  • 作者:
    M. Maglione;Christine Chen;Armenda Bialas;Aneesa Motala;Joan Chang;Olamigoke Akinniranye;S. Hempel
  • 通讯作者:
    S. Hempel
Fibroblast integrin α11β1 is a collagen assembly receptor in mechanoregulated fibrillar adhesions
成纤维细胞整合蛋白α11β1是机械调节纤维粘附中的胶原蛋白组装受体
  • DOI:
    10.1016/j.matbio.2024.10.006
  • 发表时间:
    2024-12-01
  • 期刊:
  • 影响因子:
    4.800
  • 作者:
    Moses Musiime;Pugazendhi Murugan Erusappan;Edna Cukierman;Joan Chang;Anders Molven;Uwe Hansen;Cédric Zeltz;Donald Gullberg
  • 通讯作者:
    Donald Gullberg

Joan Chang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Shifting paradigms to emerging toxins in freshwater cyanobacterial blooms
淡水蓝藻水华中新出现的毒素的范式转变
  • 批准号:
    10912318
  • 财政年份:
    2023
  • 资助金额:
    $ 160.66万
  • 项目类别:
SPX: Collaborative Research: Scalable Neural Network Paradigms to Address Variability in Emerging Device based Platforms for Large Scale Neuromorphic Computing
SPX:协作研究:可扩展神经网络范式,以解决基于新兴设备的大规模神经形态计算平台的可变性
  • 批准号:
    2401544
  • 财政年份:
    2023
  • 资助金额:
    $ 160.66万
  • 项目类别:
    Standard Grant
A Multi-Centre Non-Inferiority Randomized Controlled Trial of STOPping Cardiac MEDications in Patients with Normalized Cancer Therapy Related Cardiac Dysfunction - The STOP-MED CTRCD Trial
癌症治疗正常化相关心脏功能障碍患者停止心脏药物治疗的多中心非劣效随机对照试验 - STOP-MED CTRCD 试验
  • 批准号:
    489331
  • 财政年份:
    2023
  • 资助金额:
    $ 160.66万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 160.66万
  • 项目类别:
Functional Characterization and Development of Therapeutic Paradigms for DNA Damage Repair (DDR)-deficient Lethal Prostate Cancer
DNA 损伤修复 (DDR) 缺陷的致死性前列腺癌的功能表征和治疗范例的开发
  • 批准号:
    10675929
  • 财政年份:
    2023
  • 资助金额:
    $ 160.66万
  • 项目类别:
The Cultural Roots of STEM: A Synthesis of Non-Western STEM Learning Paradigms
STEM 的文化根源:非西方 STEM 学习范式的综合
  • 批准号:
    2313979
  • 财政年份:
    2023
  • 资助金额:
    $ 160.66万
  • 项目类别:
    Standard Grant
An International Comparative Study of the Formation and Transformation of Paradigms in the Sociological Research of Family
家庭社会学研究范式形成与转变的国际比较研究
  • 批准号:
    23K01785
  • 财政年份:
    2023
  • 资助金额:
    $ 160.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Utility of adaptive design optimization for developing rapid and reliable behavioral paradigms for substance use disorders
利用自适应设计优化来开发快速可靠的药物滥用行为范例
  • 批准号:
    10637895
  • 财政年份:
    2023
  • 资助金额:
    $ 160.66万
  • 项目类别:
CAREER: Unifying Neuroscience and Biomechanics Paradigms for Modeling Brain and Muscle Responses to Mechanical Impacts
职业:统一神经科学和生物力学范式,模拟大脑和肌肉对机械冲击的反应
  • 批准号:
    2239110
  • 财政年份:
    2023
  • 资助金额:
    $ 160.66万
  • 项目类别:
    Continuing Grant
IRES: International Paradigms for Managing Hydrologic Extremes in a Shifting Climate
IRES:气候变化中管理极端水文的国际范式
  • 批准号:
    2247036
  • 财政年份:
    2023
  • 资助金额:
    $ 160.66万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了